{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:26:10Z","timestamp":1768353970919,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det f\u00f6r H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"crossref","award":["2013-0521"],"award-info":[{"award-number":["2013-0521"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12913-018-3707-4","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T06:34:51Z","timestamp":1543386891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1896-9587","authenticated-orcid":false,"given":"Sofia Axia","family":"Karlsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Franz\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann-Marie","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervete","family":"Miftaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Eliasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Andersson Sundell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"3707_CR1","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2017. \n                    https:\/\/doi.org\/10.2337\/dc17-S012\n                    \n                  .","DOI":"10.2337\/dc17-S012"},{"key":"3707_CR2","doi-asserted-by":"publisher","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical Care in Diabetes-2018. Diabetes Care. 2018. \n                    https:\/\/doi.org\/10.2337\/dc18-S006\n                    \n                  .","DOI":"10.2337\/dc18-S006"},{"key":"3707_CR3","unstructured":"International Diabetes Federation. Cardiovascular risk protection. In: Global guideline for type 2 diabetes. Brussels: International Diabetes Federation; 2012."},{"issue":"5","key":"3707_CR4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1365-2125.2010.03895.x","volume":"71","author":"P\u00e4ivi Ruokoniemi","year":"2011","unstructured":"Ruokoniemi P, Korhonen MJ, Helin-Salmivaara A, Lavikainen P, Jula A, Junnila SYT, Kettunen R, Huupponen R. Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. Br J Clin Pharmacol. 2011. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03895.x\n                    \n                  .","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"3707_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/pds.3936","volume":"25","author":"Maarit Jaana Korhonen","year":"2015","unstructured":"Korhonen MJ, Ruokoniemi P, Ilom\u00e4ki J, Meretoja A, Helin-Salmivaara A, Huupponen R. Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes. Pharmacoepidemiol Drug Saf. 2016. \n                    https:\/\/doi.org\/10.1002\/pds.3936\n                    \n                  .","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"4","key":"3707_CR6","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bcp.12339","volume":"78","author":"Mary A. De Vera","year":"2014","unstructured":"De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014. \n                    https:\/\/doi.org\/10.1111\/bcp.12339\n                    \n                  .","journal-title":"British Journal of Clinical Pharmacology"},{"key":"3707_CR7","unstructured":"National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. \n                    https:\/\/www.nice.org.uk\/guidance\/cg181\n                    \n                  . Accessed 18 Mar 2018."},{"issue":"25 suppl 2","key":"3707_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"Neil J. Stone","year":"2013","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the american college of cardiology\/american heart association task force on practice guidelines. Circulation. 2014. \n                    https:\/\/doi.org\/10.1161\/01.cir.0000437738.63853.7a\n                    \n                  .","journal-title":"Circulation"},{"issue":"1","key":"3707_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","volume":"217","author":"Alberico L. Catapano","year":"2011","unstructured":"Catapano AL, Reiner T, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, et al. ESC\/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European atherosclerosis society (EAS). Atherosclerosis. 2011. \n                    https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.06.028\n                    \n                  .","journal-title":"Atherosclerosis"},{"issue":"39","key":"3707_CR10","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"Alberico L. Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, et al. 2016 ESC\/EAS guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw272\n                    \n                  .","journal-title":"European Heart Journal"},{"key":"3707_CR11","unstructured":"National Board of Health and Welfare. Nationella riktlinjer f\u00f6r diabetesv\u00e5rden 2010 \u2013 St\u00f6d f\u00f6r styrning och ledning. V\u00e4ster\u00e5s: Socialstyrelsen; 2010."},{"issue":"suppl_A","key":"3707_CR12","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.1093\/eurheartj\/sui003","volume":"7","author":"C.M. Ballantyne","year":"2005","unstructured":"Ballantyne CM. Changing lipid-lowering guidelines: whom to treat and how low to go. Eur Heart J Suppl. 2005. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/sui003\n                    \n                  .","journal-title":"European Heart Journal Supplements"},{"key":"3707_CR13","unstructured":"World Health Organization. Adherence to long-term therapies, evidence for action. Geneva: World Health Organization; 2003."},{"key":"3707_CR14","doi-asserted-by":"publisher","unstructured":"Oude Wesselink SF, Lingsma HF, Robben PBM, Mackenbach JP. Guideline adherence and health outcomes in diabetes mellitus type 2 patients: a cross-sectional study. BMC Health Serv Res. 2015. \n                    https:\/\/doi.org\/10.1186\/s12913-014-0669-z\n                    \n                  .","DOI":"10.1186\/s12913-014-0669-z"},{"issue":"1","key":"3707_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2011.02.002","volume":"93","author":"Soohyun Nam","year":"2011","unstructured":"Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. Diabetes Res Clin Pract. 2011. \n                    https:\/\/doi.org\/10.1016\/j.diabres.2011.02.002\n                    \n                  .","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"7","key":"3707_CR16","doi-asserted-by":"publisher","first-page":"e67611","DOI":"10.1371\/journal.pone.0067611","volume":"8","author":"Jianhua Wu","year":"2013","unstructured":"Wu J, Zhu S, Yao GL, Mohammed MA, Marshall T. Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a National Retrospective Cohort Study. PLoS One. 2013. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0067611\n                    \n                  .","journal-title":"PLoS ONE"},{"issue":"6","key":"3707_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/dme.12409","volume":"31","author":"N. R. V. Jones","year":"2014","unstructured":"Jones NRV, Fischbacher CM, Guthrie B, Leese G, Lindsay RS, McKnight JA, Pearson D, Philip S, Sattar N, Wild SH. Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008. Diabet Med. 2014. \n                    https:\/\/doi.org\/10.1111\/dme.12409\n                    \n                  .","journal-title":"Diabetic Medicine"},{"issue":"1","key":"3707_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/HJR.0b013e32833ba61e","volume":"18","author":"Mats Eriksson","year":"2010","unstructured":"Eriksson M, Zethelius B, Eeg-Olofsson K, Nilsson PM, Gudbj\u00f6rnsdottir S, Cederholm J, Eliasson B. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish national diabetes register. Eur J Prev Cardiol. 2011. \n                    https:\/\/doi.org\/10.1097\/HJR.0b013e32833ba61e\n                    \n                  .","journal-title":"European Journal of Cardiovascular Prevention & Rehabilitation"},{"issue":"1","key":"3707_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1475-2840-8-25","volume":"8","author":"Heiner K Berthold","year":"2009","unstructured":"Berthold HK, Gouni-Berthold I, B\u00f6hm M, Krone W, Bestehorn KP. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol. 2009. \n                    https:\/\/doi.org\/10.1186\/1475-2840-8-25\n                    \n                  .","journal-title":"Cardiovascular Diabetology"},{"issue":"3","key":"3707_CR20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5694\/j.1326-5377.2007.tb00835.x","volume":"186","author":"MC Thomas","year":"2007","unstructured":"Thomas MC, Nestel PJ. Management of dyslipidaemia in patients with type 2 diabetes in Australian primary care. Med J Aust. 2007;186(3):128\u201330.","journal-title":"Med J Aust"},{"issue":"4","key":"3707_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/clc.22503","volume":"39","author":"Yashashwi Pokharel","year":"2016","unstructured":"Pokharel Y, Akeroyd JM, Ramsey DJ, Hira RS, Nambi V, Shah T, Woodard LD, Winchester DE, Ballantyne CM, Petersen LA, et al. Statin use and its facility-level variation in patients with diabetes: insight from the veterans affairs National Database. Clin Cardiol. 2016. \n                    https:\/\/doi.org\/10.1002\/clc.22503\n                    \n                  .","journal-title":"Clinical Cardiology"},{"issue":"6","key":"3707_CR22","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/ndt\/gfh771","volume":"20","author":"George R. Bailie","year":"2005","unstructured":"Bailie GR, Eisele G, Liu L, Roys E, Kiser M, Finkelstein F, Wolfe R, Port F, Burrows-Hudson S, Saran R. Patterns of medication use in the RRI-CKD study: focus on medications with cardiovasculars effects. Nephrol Dial Transplant. 2005. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfh771\n                    \n                  .","journal-title":"Nephrology Dialysis Transplantation"},{"key":"3707_CR23","doi-asserted-by":"publisher","first-page":"S291","DOI":"10.1016\/S0168-8227(14)70732-6","volume":"106","author":"Bj\u00f6rn Eliasson","year":"2014","unstructured":"Eliasson B, Gudbj\u00f6rnsdottir S. Diabetes care - improvement through measurement. Diabetes Res Clin Pract. 2014. \n                    https:\/\/doi.org\/10.1016\/S0168-8227(14)70732-6\n                    \n                  .","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"13","key":"3707_CR24","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jacc.2010.01.013","volume":"55","author":"Klas Gr\u00e4nsbo","year":"2010","unstructured":"Gr\u00e4nsbo K, Melander O, Wallentin L, Lindb\u00e4ck J, Stenestrand U, Carlsson J, Nilsson J. Cardiovascular and Cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol. 2010. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2010.01.013\n                    \n                  .","journal-title":"Journal of the American College of Cardiology"},{"issue":"15","key":"3707_CR25","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1001\/jama.291.15.1864","volume":"291","author":"Dennis T. Ko","year":"2004","unstructured":"Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. J Am Med Assoc. 2004. \n                    https:\/\/doi.org\/10.1001\/jama.291.15.1864\n                    \n                  .","journal-title":"JAMA"},{"issue":"11","key":"3707_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.jacc.2015.07.018","volume":"66","author":"Xavier Rossello","year":"2015","unstructured":"Rossello X, Pocock SJ, Julian DG. Long-term use of cardiovascular drugs challenges for research and for patient care. J Am Coll Cardiol. 2015. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2015.07.018\n                    \n                  .","journal-title":"Journal of the American College of Cardiology"},{"issue":"1-3","key":"3707_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000452727","volume":"43","author":"George A. Kaysen","year":"2017","unstructured":"Kaysen GA. Lipid-lowering therapy in CKD. Should we use it and in which patients. Blood Purif. 2017. \n                    https:\/\/doi.org\/10.1159\/000452727\n                    \n                  .","journal-title":"Blood Purification"},{"issue":"11","key":"3707_CR28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1177\/2047487313494292","volume":"21","author":"B Eliasson","year":"2013","unstructured":"Eliasson B, Gudbj\u00f6rnsdottir S, Zethelius B, Eeg-Olofsson K, Cederholm J. LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes. Eur J Prev Cardiol. 2014. \n                    https:\/\/doi.org\/10.1177\/2047487313494292\n                    \n                  .","journal-title":"European Journal of Preventive Cardiology"},{"issue":"3","key":"3707_CR29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/dme.13007","volume":"33","author":"C. Hero","year":"2015","unstructured":"Hero C, Svensson AM, Gidlund P, Gudbj\u00f6rnsdottir S, Eliasson B, Eeg-Olofsson K. LDL cholesterol is not a good marker of cardiovascular risk in type 1 diabetes. Diabet Med. 2016. \n                    https:\/\/doi.org\/10.1111\/dme.13007\n                    \n                  .","journal-title":"Diabetic Medicine"},{"key":"3707_CR30","unstructured":"National Board of Health and Welfare. Nationella riktlinjer f\u00f6r diabetesv\u00e5rden 2015 \u2013 St\u00f6d f\u00f6r styrning och ledning. Falun: Socialstyrelsen; 2015."},{"key":"3707_CR31","volume-title":"Att f\u00f6rebygga aterosklerotisk hj\u00e4rt-k\u00e4rlsjukdom med l\u00e4kemedel - behandlingsrekommendation","author":"Swedish Medical product Agency","year":"2014","unstructured":"Swedish Medical product Agency. Att f\u00f6rebygga aterosklerotisk hj\u00e4rt-k\u00e4rlsjukdom med l\u00e4kemedel - behandlingsrekommendation. 2014 \n                    https:\/\/lakemedelsverket.se\/upload\/halso-och-sjukvard\/behandlingsrekommendationer\/Att_forebygga_aterosklerotisk_hjart-karlsjukdom_med%20_lakemedel_behandlingsrekommendation.pdf\n                    \n                  . Accessed 19 Mar 2018."},{"issue":"2","key":"3707_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.diabres.2011.05.037","volume":"93","author":"Bj\u00f6rn Zethelius","year":"2011","unstructured":"Zethelius B, Eliasson B, Eeg-Olofsson K, Svensson AM, Gudbjornsdottir S, Cederholm J. A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract. 2011. \n                    https:\/\/doi.org\/10.1016\/j.diabres.2011.05.037\n                    \n                  .","journal-title":"Diabetes Research and Clinical Practice"},{"key":"3707_CR33","volume-title":"Riskmotorer f\u00f6r typ 1 och typ 2 diabetes","author":"National Diabetes Register","year":"2018","unstructured":"National Diabetes Register. Riskmotorer f\u00f6r typ 1 och typ 2 diabetes. 2018. \n                    https:\/\/www.ndr.nu\/#\/risk\n                    \n                  . Accessed 14 Feb 2018."},{"key":"3707_CR34","doi-asserted-by":"publisher","unstructured":"Keller H, Hirsch O, Kaufmann-Kolle P, Krones T, Becker A, S\u00f6nnichsen AC, Baum E, Donner-Banzhoff N. Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis. BMC Public Health. 2013. \n                    https:\/\/doi.org\/10.1186\/1471-2458-13-623\n                    \n                  .","DOI":"10.1186\/1471-2458-13-623"},{"issue":"2","key":"3707_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jval.2013.12.010","volume":"17","author":"Folgerdiena M. de Vries","year":"2014","unstructured":"De Vries FM, Denig P, Visser ST, Hak E, Postma MJ. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands. Value Health. 2014. \n                    https:\/\/doi.org\/10.1016\/j.jval.2013.12.010\n                    \n                  .","journal-title":"Value in Health"},{"issue":"2","key":"3707_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2165\/11531910-000000000-00000","volume":"30","author":"L. Annemans","year":"2010","unstructured":"Annemans L, Marbaix S, Webb K, Van Gaal L, Scheen A. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population. Clin Drug Invest. 2010. \n                    https:\/\/doi.org\/10.2165\/11531910-000000000-00000\n                    \n                  .","journal-title":"Clinical Drug Investigation"},{"issue":"5","key":"3707_CR37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.acvd.2008.05.003","volume":"101","author":"Antoine Lafuma","year":"2008","unstructured":"Lafuma A, Colin X, Solesse A. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS. Arch Cardiovasc Dis. 2008. \n                    https:\/\/doi.org\/10.1016\/j.acvd.2008.05.003\n                    \n                  .","journal-title":"Archives of Cardiovascular Diseases"},{"issue":"1","key":"3707_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pcd.2017.09.003","volume":"12","author":"Rebecka Husdal","year":"2018","unstructured":"Husdal R, Rosenblad A, Leksell J, Eliasson B, Jansson S, Jerd\u00e9n L, St\u00e5lhammar J, Steen L, Wallman T, Svensson AM, et al. Resources and organisation in primary health care are associated with HbA1c level: a nationwide study of 230 958 people with type 2 diabetes mellitus. Prim Care Diabetes. 2018. \n                    https:\/\/doi.org\/10.1016\/j.pcd.2017.09.003\n                    \n                  .","journal-title":"Primary Care Diabetes"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3707-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-018-3707-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3707-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T19:09:47Z","timestamp":1574881787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-018-3707-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3707"],"URL":"https:\/\/doi.org\/10.1186\/s12913-018-3707-4","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"21 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Regional Ethical Review Board at the University of Gothenburg (Reg. no. 1173-16). Individual consent was not required for the present study. However, all patients have given their informed consent to be included in the Swedish National Diabetes Register.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KAS is employed by AstraZeneca. However, the views expressed in this article are her own and not those of AstraZeneca\u2019s. All other authors declare that they have no competing interests associated with their contribution to the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"900"}}